16 Lymphoma Clinical Trials in Philadelphia, PA (2026)

Q: How do I join a clinical trial in Philadelphia?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Philadelphia research site will contact you.

Recruiting Lymphoma Studies in Philadelphia

NCT06564038Recruiting

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

The purpose of this study is to assess the safety and efficacy of AZD0486 administered as monotherapy or in combination with other anticancer agents in participants with hematological malignancies....

Philadelphia, PAPHASE1408 participantsAstraZeneca

View Study Details

NCT07082803Recruiting

TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas

The primary purpose of this study is to evaluate the safety, pharmacokinetics,, and preliminary anti-tumor activity of TLN-121 as a single agent and in combination with other anti-lymphoma therapies i...

Philadelphia, PAPHASE1180 participantsTreeline Biosciences, Inc.

View Study Details

NCT06137144Recruiting

AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies.

This study is designed to evaluate the safety, tolerability, PK and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in p...

Philadelphia, PAPHASE1161 participantsAstraZeneca

View Study Details

NCT04827810Recruiting

A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer

This is a first-in-human, phase I, open-label, non-randomized dose-escalation and dose-expansion study with the primary objective to determine the safety profile of small molecule, mitochondrial-targe...

Philadelphia, PAPHASE142 participantsFox Chase Cancer Center

View Study Details

NCT07451054Recruiting

CD45BE-HSPC + CART-45 Cells

This is a phase 1, open-label, dose-finding study to assess the safety, feasibility, pharmacokinetics and preliminary efficacy of autologous base edited anti-CD45 CAR T cells (referred to as "CART-45 ...

Philadelphia, PAPHASE142 participantsUniversity of Pennsylvania

View Study Details

NCT06544265Recruiting

SynKIR-310 for Relapsed/Refractory B-NHL

This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refrac...

Philadelphia, PAPHASE136 participantsVerismo Therapeutics

View Study Details

NCT06934382Recruiting

Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma

This will be a Phase 1, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with R/R T-ALL or T-LLy. BEAM-201 is an allogeneic anti-CD7 CART therapy....

Philadelphia, PAPHASE133 participantsStephan Grupp MD PhD

View Study Details

NCT06458439Recruiting

Epcoritamab-CAR T Cells for Large B-cell Lymphomas

This study investigates the feasibility and efficacy of epcoritamab treatment before CAR T cells. This study also investigates if, when patients have residual lymphoma after CAR T cells, epcoritamab c...

Philadelphia, PAPHASE231 participantsAbramson Cancer Center at Penn Medicine

View Study Details

NCT06420089Recruiting

CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)

This is an open-label phase I study to determine the safety and recommended phase 2 dose (RP2D) of Senza5 CART5 cells in patients with relapsed or refractory CD5 positive nodal T cell NHL. RP2D will b...

Philadelphia, PAPHASE130 participantsVittoria Biotherapeutics

View Study Details

NCT07586618Recruiting

First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.

ALT-101 is a first-in-human Phase 1 clinical trial testing a new antibody drug called 4A10 in patients with relapsed or hard-to-treat acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma. 4A1...

Philadelphia, PAPHASE124 participantsAllterum Therapeutics, Inc

View Study Details

NCT05077527Recruiting

Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

This phase I trial evaluates the side effects and usefulness of axicabtagene clioleucel (a CAR-T therapy) and find out what effect, if any, it has on treating patients with HIV-associated aggressive B...

Philadelphia, PAPHASE120 participantsAIDS Malignancy Consortium

View Study Details

NCT04139304Recruiting

A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

This feasibility trial studies how well daratumumab in combination with dose-adjusted etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride (DA-EPOCH) works in tr...

Philadelphia, PAEARLY_PHASE115 participantsAIDS Malignancy Consortium

View Study Details

NCT07478848Recruiting

Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas

This clinical trial assesses whether it is feasible to use radiation therapy with vancomycin prior to CAR T-cell therapy for patients with large B-cell lymphomas...

Philadelphia, PAPHASE114 participantsAbramson Cancer Center at Penn Medicine

View Study Details

NCT06607549Recruiting

Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)

The purpose of this clinical trial is to learn if drugs loncastuximab tesirine and rituximab (lonca-R) after stereotactic radiosurgery are safe and effective for treatment of central nervous system ly...

Philadelphia, PAPHASE112 participantsUniversity of Utah

View Study Details

NCT07343934Recruiting

huCART19-IL18-eDHFR Cells in Relapsed/Refractory Follicular Lymphoma

This is a phase 1, open-label study to evaluate the feasibility, safety and preliminary efficacy of huCART19-IL18-eDHFR cells administered in patients with relapsed or refractory follicular lymphoma. ...

Philadelphia, PAPHASE16 participantsUniversity of Pennsylvania

View Study Details

NCT06610344Recruiting

BHB & CAR-T for Lymphomas

The aim of this study is to assess the feasibility of β-hydroxybutyrate (BHB) supplementation in individuals who are receiving therapy for lymphoma with standard-of-care anti-CD19 CAR T-cells (CAR-T) ...

Philadelphia, PANA5 participantsAbramson Cancer Center at Penn Medicine

View Study Details

About Lymphoma Clinical Trials in Philadelphia

Lymphoma is a cancer of the lymphatic system that affects infection-fighting cells called lymphocytes. The two main types are Hodgkin lymphoma and non-Hodgkin lymphoma. Treatment often includes chemotherapy, radiation, immunotherapy, and in some cases stem cell transplant.

There are currently 16 lymphoma clinical trials recruiting participants in Philadelphia, PA. These studies are seeking a combined 1,059 participants. Research is being sponsored by AstraZeneca, Treeline Biosciences, Inc., Fox Chase Cancer Center and 8 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Lymphoma Clinical Trials in Philadelphia — FAQ

Are there lymphoma clinical trials in Philadelphia?

Yes, there are 16 lymphoma clinical trials currently recruiting in Philadelphia, PA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Philadelphia?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Philadelphia research site will contact you about next steps.

Are clinical trials in Philadelphia free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Philadelphia studies also compensate for your time and travel.

What lymphoma treatments are being tested?

The 16 active trials in Philadelphia are testing new therapies including novel drugs, biologics, and treatment approaches for lymphoma.

Data updated September 7, 2026 from ClinicalTrials.gov